Shares in Lupin Ltd gained 3.2 per cent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the US regulator.
Shares in Lupin Ltd gained 3.2 per cent after the company got the final approval from the U.S. Food and Drug Administration for a generic version of eye drop Gatifloxacin on Friday, according to the web site of the US regulator.
Gatifloxacin treats conjunctivitis, or more commonly called pink eye, and is produced by Allergan Inc.
A Lupin spokesman was not immediately reachable for comment.
Copyright: Thomson Reuters 2013
Sign Up with Google
ADVERTISEMENT
RECOMMENDED FOR YOU
POPULAR
1
CCI Probes Ultratech For Alleged Cartelisation In ONGC Tenders
2
Jane Street Trades Head For Long-Drawn SEBI Investigation
3
Seven Premium Smartphones Under Rs 50,000 In India: Oppo Reno 14 Pro, Realme GT 7, Vivo T4 Ultra, More
4
Trade Deals Not Bound By Deadlines, Says Piyush Goyal Amid India-US BTA Talks
5